Posted by Michael Wonder on 14 Jul 2022
FDA grants Alpheus Medical orphan drug and fast track designations for novel sonodynamic therapy for brain cancer
13 July 2022 - The company is currently enrolling patients in a multicentre Phase 1 clinical trial for the treatment of recurrent glioblastoma.
Alpheus Medical today announced the U.S. FDA has granted both orphan drug and fast track designations to Alpheus Medical's CV-01 delivery of sonodynamic therapy as a potential treatment for patients with recurrent glioblastoma, the most common primary brain cancer, and other malignant gliomas.
